Diagnovus has announced the launch of a gene expression assay, ENGAUGE-cancer-DLBCL, designed for use in patients with diffuse large B-cell lymphoma (DLBCL).
The assay, which combines patients International Prognostic Index (IPI) score and the results, studies underlying tumor biology of patients and allows physicians to make more informed treatment decisions.
Stanford University School of Medicine lymphoma program leader Ron Levy said traditional stratification schemes based on clinical characteristics such as the IPI have provided prognostic guidance in the management of patients with DLBCL.
"Despite the ease of use, IPI does not fully capture disease heterogeneity, and it is common to have two patients with identical IPI risk scores have very different outcomes," Levy added.
University of Miami lymphoma head Dr Izidore Lossos said, "Knowledge of molecular prognostic markers may identify cellular mechanisms leading to the recognition of specific molecular targets for new therapeutic approaches."
In addition, the assay uses routinely available formalin-fixed, paraffin-embedded (FFPE) diagnostic biopsy tissue and performs the assay in a reproducible and accurate manner, according to the company.
